Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Anti-Diabetic Effect of Telmisartan Through its Partial PPARγ-Agonistic Activity

Muluken Altaye Ayza, Kaleab Alemayehu Zewdie, Bekalu Amare Tesfaye, Selamawit Tesfamariam Gebrekirstos, Derbew Fikadu Berhe Department of Pharmacology and Toxicology, School of Pharmacy, Mekelle University, Mekelle, EthiopiaCorrespondence: Muluken Altaye Ayza Tel +251-916707913 Email Mulealto1@gmail...

Full description

Bibliographic Details
Main Authors:	Ayza MA, Zewdie KA, Tesfaye BA, Gebrekirstos ST, Berhe DF
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-10-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	diabetes mellitus hypertension peroxisome proliferator-activated receptors telmisartan
Online Access:	https://www.dovepress.com/anti-diabetic-effect-of-telmisartan-through-its-partial-ppargamma-agon-peer-reviewed-article-DMSO

Similar Items

Involvement of PPAR-γ in the neuroprotective and anti-inflammatory effects of angiotensin type 1 receptor inhibition: effects of the receptor antagonist telmisartan and receptor deletion in a mouse MPTP model of Parkinson's disease
by: Garrido-Gil Pablo, et al.
Published: (2012-02-01)

SARTANS OF THE SECOND GENERATION: THERAPEUTIC POTENTIAL EXTENSION
by: S. V. Nedogoda
Published: (2016-01-01)

Telmisartan Attenuates Kanamycin-Induced Ototoxicity in Rats
by: Chang Ho Lee, et al.
Published: (2021-11-01)

The Antihypertensive Efficacy of Chlorthalidone and Telmisartan in Indian Hypertensive Patients who were Uncontrolled with Hydrochlorothiazide and Telmisartan Combination-A Prospective and an Open Label Study
by: Suresh V Sagarad, et al.
Published: (2014-04-01)

A multicenter, open-label study of the efficacy and safety of telmisartan in mild to moderate hypertensive patients
by: Plavnik Frida Liane, et al.
Published: (2002-01-01)

Antiproliferative and apoptotic effects of telmisartan in human glioma cells
by: Yung-Lung Chang, et al.
Published: (2023-06-01)

Immune pleiotropic effect of telmisartan in arterial hypertension
by: N. M. Agarkov, et al.
Published: (2022-07-01)

A comparative study on the pleiotropic effects of Olmesartan and Telmisartan in hypertensive patients with type 2 diabetes mellitus: A randomized, prospective, open labelled, hospital based study
by: Vineela Karthik N, et al.
Published: (2023-07-01)

The PPAR-gamma agonist pioglitazone protects cortical neurons from inflammatory mediators via improvement in peroxisomal function
by: Gray Elizabeth, et al.
Published: (2012-04-01)

Comparative Study of High Dose Mono-Therapy of Amlodipine or Telmisartan, and Their Low Dose Combination in Mild to Moderate Hypertension
by: Jaswant Goyal, et al.
Published: (2014-06-01)

Features of change of intracardiac gemodynamics and functional state of myocardium under the impact of telmisartan in patients with hypertension
by: Koshlia V.I., et al.
Published: (2016-09-01)

Features of change of intracardiac gemodynamics and functional state of myocardium under the impact of telmisartan in patients with hypertension.
by: V. I. Koshlia, et al.
Published: (2015-09-01)

Efecto de telmisartan sobre marcadores del remodelado óseo en pacientes hipertensos Telmisartan effect's on remodelling bone markers in hypertensive patients
by: J. L. Pérez-Castrillón, et al.
Published: (2012-02-01)

Effect of Telmisartan on the Regression of the Left Ventricular Hypertrophy in the Patients of Essential Hypertension
by: Kumar Haraprasad Misra, et al.
Published: (2013-07-01)

Telmisartan induces osteosarcoma cells growth inhibition and apoptosis via suppressing mTOR pathway
by: Wang Chao, et al.
Published: (2018-07-01)

Telmisartan and cardioprotection
by: McFarlane S
Published: (2011-11-01)

TELMISARTAN IN THE TREATMENT OF ARTERIAL HYPERTENSION. CASE STUDY
by: V. I. Podzolkov, et al.
Published: (2015-12-01)

A Meta-analysis of antihypertensive effect of telmisartan versus candesartan in patients with essential hypertension
by: Di Zhao, et al.
Published: (2019-01-01)

Effects of telmisartan on metabolic syndrome components: a comprehensive review
by: Mohsen Imenshahidi, et al.
Published: (2024-02-01)

Oleamide activates peroxisome proliferator-activated receptor gamma (PPARγ) <it>in vitro</it>
by: Dionisi Mauro, et al.
Published: (2012-05-01)

Efficacy and Safety of Coadministered Ezetimibe–Rosuvastatin plus Telmisartan in South Korean Patients with Dyslipidemia and Hypertension: A Multicenter, Randomized, Double-Blind, Active-Controlled, Phase III Trial
by: Zhao-Yan Song, et al.
Published: (2023-03-01)

Cardiometabolic properties of telmisartan: new perspectives for use
by: O. M. Drapkina, et al.
Published: (2015-12-01)

Synthetic and natural Peroxisome Proliferator-Activated Receptor (PPAR) agonists as candidates for the therapy of the metabolic syndrome
by: Tan, Chek Kun, et al.
Published: (2017)

The potential anticancer activities of telmisartan – a literature review
by: Andriana Hadjiyianni, et al.
Published: (2023-09-01)

Influence of additional risk factors on the antihypertensive efficacy of eprosartan and telmisartan in patients with essential hypertension
by: V. V. Syvolap, et al.
Published: (2017-12-01)

Efficacy and Safety of Triple Therapy of Telmisartan/Amlodipine/Rosuvastatin in Patients with Dyslipidemia and Hypertension: A Multicenter Randomized Clinical Trial
by: Sungjoon Park, MD, et al.
Published: (2024-01-01)

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
by: Chi-Hung Liu, et al.
Published: (2020-01-01)

Role of GW0742 A PPARβ/δ Agonist on Coronary Angiogenesis in Control and Diabetic Rats
by: Ensieh Salehi, et al.
Published: (2011-08-01)

Efficacy and safety of low‐dose antihypertensive combination of amlodipine, telmisartan, and chlorthalidone: A randomized, double‐blind, parallel, phase II trial
by: Ki‐Chul Sung, et al.
Published: (2022-10-01)

Blood pressure-lowering effect of telmisartan compared to losartan among mild to moderate essential hypertensive adult subjects: A meta-analysis
by: Kusum Kumari, et al.
Published: (2022-01-01)

Study of Changes in Renal Function by Perindopril and Telmisartan during Treatment of Systemic Hypertension
by: MANISH KUMAR, et al.
Published: (2014-04-01)

Effects of telmisartan vs olmesartan on metabolic parameters, insulin resistance and adipocytokines in hypertensive obese patients Efectos de telmisartan vs olmesartan sobre parámetros antropométricos, resistencia a la insulina y adipocitoquinas en pacientes hipertensos obesos
by: D. A. de Luis, et al.
Published: (2010-04-01)

Understanding the pH Dependence of Supersaturation State—A Case Study of Telmisartan
by: Szabina Kádár, et al.
Published: (2022-08-01)

Telmisartan Potentiates Insulin Secretion via Ion Channels, Independent of the AT1 Receptor and PPARγ
by: Tao Liu, et al.
Published: (2021-09-01)

The telmisartan and amlodipine combination in the treatment of hypertension
by: G G Shehyan, et al.
Published: (2014-03-01)

Efficient and improved synthesis of Telmisartan
by: A. Sanjeev Kumar, et al.
Published: (2010-03-01)

Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double‐blind, multicenter, therapeutic confirmatory, phase III clinical trial
by: Chan Joo Lee, et al.
Published: (2024-03-01)

Effect of Telmisartan in amelioration inflammatory Responses Induced by Myocardial Ischemia/Reperfusion Injury IN male Mice
by: Najah Rayish Hadia, et al.
Published: (2017-12-01)

A study of the effects Telmisartan on induced hyperlipidemia and atherosclerosis in male rabbits
by: Shatha M. Al-Safi, et al.
Published: (2010-06-01)

Central blood pressure lowering effect of telmisartan‐rosuvastatin single‐pill combination in hypertensive patients combined with dyslipidemia: A pilot study
by: JungMin Choi, et al.
Published: (2021-09-01)